Literature DB >> 21258931

Vascular characterisation of triple negative breast carcinomas using dynamic MRI.

Sonia P Li1, Anwar R Padhani, N Jane Taylor, Mark J Beresford, Mei-Lin W Ah-See, J James Stirling, James A d'Arcy, David J Collins, Andreas Makris.   

Abstract

OBJECTIVES: Triple-negative (ER-/PR-/HER2-) breast carcinomas (TNBC) are aggressive tumours with underexplored imaging features. This study investigates whether their vascular characteristics as assessed by dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast-enhanced (DSC) MRI are distinct from the prognostically more favourable ER+/PR+/HER2- cancers.
METHODS: Patients with primary breast cancer underwent MRI before neoadjuvant chemotherapy and were identified as ER-/PR-/HER2- or ER+/PR+/HER2- from core biopsy specimens. MRI parameters reflecting tissue perfusion, permeability, and extracellular leakage space were measured. Values for inflow transfer constant (K(trans)), outflow rate constant (k(ep)), leakage space (v(e)), area under the gadolinium curve (IAUGC(60) ), relative blood volume (rBV) and flow (rBF), and Mean Transit Time (MTT) were compared across receptor status and with known prognostic variables.
RESULTS: Thirty seven patients were assessable in total (16 ER-/PR-/HER2-, 21 ER+/PR+/HER2-). Lower v(e) (p = 0.001), shorter MTT (p = 0.007) and higher k(ep) values (p = 0.044) were observed in TNBC. v(e) was lower across all T stages, node-negative (p = 0.004) and low-grade TNBC (p = 0.037). v(e) was the best predictor of triple negativity (ROC AUC 0.80).
CONCLUSIONS: TNBC possess characteristic features on imaging, with lower extracellular space (higher cell density) and higher contrast agent wash-out rate (higher vascular permeability) suggesting a distinctive phenotype detectable by MRI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21258931     DOI: 10.1007/s00330-011-2061-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  36 in total

1.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

2.  Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics.

Authors:  G J Parker; J Suckling; S F Tanner; A R Padhani; P B Revell; J E Husband; M O Leach
Journal:  J Magn Reson Imaging       Date:  1997 May-Jun       Impact factor: 4.813

3.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Computer-aided interpretation of dynamic magnetic resonance imaging reflects histopathology of invasive breast cancer.

Authors:  Pascal A T Baltzer; Tibor Vag; Matthias Dietzel; Sebastian Beger; Christian Freiberg; Mieczyslaw Gajda; Oumar Camara; Werner A Kaiser
Journal:  Eur Radiol       Date:  2010-03-04       Impact factor: 5.315

Review 5.  Microenvironmental and cellular consequences of altered blood flow in tumours.

Authors:  N Raghunand; R A Gatenby; R J Gillies
Journal:  Br J Radiol       Date:  2003       Impact factor: 3.039

6.  Triple-negative breast cancer: correlation between imaging and pathological findings.

Authors:  Eun Sook Ko; Byung Hee Lee; Hyun-A Kim; Woo-Chul Noh; Min Suk Kim; Sang-Ah Lee
Journal:  Eur Radiol       Date:  2009-11-07       Impact factor: 5.315

Review 7.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Authors:  Ana Bosch; Pilar Eroles; Rosa Zaragoza; Juan R Viña; Ana Lluch
Journal:  Cancer Treat Rev       Date:  2010-01-08       Impact factor: 12.111

8.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.

Authors:  A Bergamaschi; E Tagliabue; T Sørlie; B Naume; T Triulzi; R Orlandi; H G Russnes; J M Nesland; R Tammi; P Auvinen; V-M Kosma; S Ménard; A-L Børresen-Dale
Journal:  J Pathol       Date:  2008-02       Impact factor: 7.996

9.  Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

Authors:  B K Linderholm; H Hellborg; U Johansson; G Elmberger; L Skoog; J Lehtiö; R Lewensohn
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976

Review 10.  What is triple-negative breast cancer?

Authors:  William J Irvin; Lisa A Carey
Journal:  Eur J Cancer       Date:  2008-11-12       Impact factor: 9.162

View more
  22 in total

1.  Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.

Authors:  Stylianos Drisis; Thierry Metens; Michael Ignatiadis; Konstantinos Stathopoulos; Shih-Li Chao; Marc Lemort
Journal:  Eur Radiol       Date:  2015-08-27       Impact factor: 5.315

2.  Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results.

Authors:  Andreas Stadlbauer; Max Zimmermann; Barbara Bennani-Baiti; Thomas H Helbich; Pascal Baltzer; Paola Clauser; Panagiotis Kapetas; Zsuzsanna Bago-Horvath; Katja Pinker
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

3.  Triple-negative breast cancers: associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers.

Authors:  Martine Boisserie-Lacroix; Gaëtan Macgrogan; Marc Debled; Stéphane Ferron; Maryam Asad-Syed; Pippa McKelvie-Sebileau; Simone Mathoulin-Pélissier; Véronique Brouste; Gabrielle Hurtevent-Labrot
Journal:  Oncologist       Date:  2013-07-02

4.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.

Authors:  Ji Hyun Youk; Eun Ju Son; Jin Chung; Jeong-Ah Kim; Eun-Kyung Kim
Journal:  Eur Radiol       Date:  2012-04-17       Impact factor: 5.315

5.  Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients?

Authors:  Boram Yi; Doo Kyoung Kang; Dukyong Yoon; Yong Sik Jung; Ku Sang Kim; Hyunee Yim; Tae Hee Kim
Journal:  Eur Radiol       Date:  2014-02-21       Impact factor: 5.315

6.  Diagnostic performance of initial enhancement analysis using ultra-fast dynamic contrast-enhanced MRI for breast lesions.

Authors:  Mariko Goto; Koji Sakai; Hajime Yokota; Maki Kiba; Mariko Yoshida; Hiroshi Imai; Elisabeth Weiland; Isao Yokota; Kei Yamada
Journal:  Eur Radiol       Date:  2018-08-07       Impact factor: 5.315

7.  Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging.

Authors:  Eva M Fallenberg; Diane M Renz; Bettina Karle; Carsten Schwenke; Barbara Ingod-Heppner; Angela Reles; Florian J Engelken; Alexander Huppertz; Bernd Hamm; Matthias Taupitz
Journal:  Eur Radiol       Date:  2014-09-25       Impact factor: 5.315

8.  Diagnostic value of contrast-enhanced ultrasound parametric imaging in breast tumors.

Authors:  Zhang Yuan; Jiang Quan; Zhang Yunxiao; Chen Jian; He Zhu; Gong Liping
Journal:  J Breast Cancer       Date:  2013-06-28       Impact factor: 3.588

9.  Kinetic volume analysis on dynamic contrast-enhanced MRI of triple-negative breast cancer: associations with survival outcomes.

Authors:  Yoko Hayashi; Hiroko Satake; Satoko Ishigaki; Rintaro Ito; Mariko Kawamura; Hisashi Kawai; Shingo Iwano; Shinji Naganawa
Journal:  Br J Radiol       Date:  2019-12-16       Impact factor: 3.039

10.  The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them.

Authors:  Martyn T Smith; Kathryn Z Guyton; Nicole Kleinstreuer; Alexandre Borrel; Andres Cardenas; Weihsueh A Chiu; Dean W Felsher; Catherine F Gibbons; William H Goodson; Keith A Houck; Agnes B Kane; Michele A La Merrill; Herve Lebrec; Leroy Lowe; Cliona M McHale; Sheroy Minocherhomji; Linda Rieswijk; Martha S Sandy; Hideko Sone; Amy Wang; Luoping Zhang; Lauren Zeise; Mark Fielden
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-03-09       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.